Sparrow Pharmaceuticals has filed a notice of an exempt offering of securities to raise $15,251,730.00 in New Debt Financing.
According to filings with the U.S. Securities and Exchange Commission, Sparrow Pharmaceuticals is raising up to $15,251,730.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Jacks played a…
